Skip to main content
. 2015 Jun 23;5:127. doi: 10.3389/fonc.2015.00127

Figure 3.

Figure 3

(A) Overall survival for lung cancer patients treated with esophagus and normal lung-sparing IMRT vs. standard technique. (B) Overall survival for patients with stage II–IIIB non-small cell lung cancer receiving definitive chemoradiation treated with esophagus and normal lung-sparing IMRT vs. standard technique.